Congenital endplate acetylcholinesterase deficiency responsive to ephedrine.

Bestue-Cardiel, M; Sáenz de Cabezón-Alvarez, A; Capablo-Liesa, J L; López-Pisón, J; Peña-Segura, J L; Martin-Martinez, J; Engel, A G · Neurology · 2005

case_report · Level V

Where this comes from

Abstract

The authors describe two patients with congenital myasthenic syndrome (CMS) with end plate acetylcholinesterase (AChE) deficiency caused by mutations in the collagenic tail (ColQ) of AChE: a homozygous C-terminal Y230S mutation in Patient 1 and Y430S and a C-terminal splice-site mutation in Patient 2. In Patient 1, a Prostigmin (neostigmine bromide) test failed to distinguish between AChE deficiency and a slow-channel CMS. Both patients responded dramatically to ephedrine therapy.

Medical subject headings